COPD Health Management
Smart lung attack prediction
You are not alone
There are many uncertainties for people living with COPD. A lung attack can occur at any given moment and existing tests often indicated the emergence of attacks too late.
Nearly 1 in 8 adults suffer from COPD
Empowering COPD patients
COPD Patients can experience lung attacks, triggered by lung inflammation. Early inflammation already releases molecules that can be detected in breath.
With RespiQ clinicians can remotely review patients’ health status allowing earlier medical intervention and preventing or mitigating lung attacks.
Faster testing
Smarter analysis
Better wellbeing
How it works
-
Our compact device is designed for at-home use. Simply pick up the breath sampler, exhale into the sampler and click it back into the base station for analysis.
-
Once the sampler is rejoined with the analyzer base station, the device automatically will analyze your breath. This is fully automatic and will take a minute to complete.
-
Upon analyzing the results, the device will provide a brief confirmation the measurement was successful. If anything is amiss, the device will indicate and you can simply re-take the test.
-
Upon confirming measurement success, the device will share the results with your healthcare provider, and notify if anything is amiss. You will only hear if attention is needed from your healthcare provider.
-
The advantage of regular sampling is that the device can improve its prediction accuracy: the more you use it the better results will become, positively impacting your health and time spent.
COPD facts
According to the WHO, COPD is the third leading cause of death worldwide, with well over 300M patients worldwide. About ~15% are severe patients (gold class III & IV), at risk of annual hospitalization.
Research shows that 18% of patients cause 65% of COPD hospitalizations, primarily caused by lung exacerbations. Reducing exacerbations significantly increases quality-adjusted life years (QALYs).
Early COPD warning tools offer highly favorable incremental cost-effectiveness ratios (ICERs) by significantly increasing QALYs above the nominal symptom-driven trajectory.
Take control of your respiratory health
It’s as simple as breathing